Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TOI
stocks logo

TOI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
--
--
-0.090
-35.71%
--
--
-0.093
-55.56%
Estimates Revision
The market is revising Upward the revenue expectations for The Oncology Institute, Inc. (TOI) for FY2025, with the revenue forecasts being adjusted by 5.36% over the past three months. During the same period, the stock price has changed by -2.12%.
Revenue Estimates for FY2025
Revise Upward
up Image
+5.36%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+8.86%
In Past 3 Month
Stock Price
Go Down
down Image
-2.12%
In Past 3 Month
Wall Street analysts forecast TOI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOI is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast TOI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOI is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.230
sliders
Low
6.00
Averages
7.00
High
8.00
Current: 3.230
sliders
Low
6.00
Averages
7.00
High
8.00
Needham
Buy
initiated
$5
2025-11-25
Reason
Needham
Price Target
$5
2025-11-25
initiated
Buy
Reason
Needham initiated coverage of Oncology Institute with a Buy rating and $5 price target. As value-based care adoption accelerates, Oncology Institute appears well positioned to help curb rising oncology costs, with early relationships typically starting in fee-for-service and expanding into downside risk, the analyst tells investors in a research note. Demand supports a durable 20%+ growth outlook, a shift toward VBC could lift EBITDA margins into the mid-single digits, and shares look undervalued ahead of expected positive EBITDA in Q4 and FY26, the firm says.
Needham
Matthew Shea
initiated
$5
2025-11-25
Reason
Needham
Matthew Shea
Price Target
$5
2025-11-25
initiated
Reason
Needham analyst Matthew Shea initiated coverage of Oncology Institute with a Buy rating and $5 price target. The need for solutions that can mitigate oncology cost trends "could not be more apparent," says the analyst, who views Oncology Institute as "a critical player in addressing this gap." The firm sees demand seeding durable 20%-plus topline growth and sees an opportunity for EBITDA margins to scale towards mid-single digits over the medium term as mix shifts towards value-based care, the analyst tells investors.
Noble Capital
Outperform
initiated
$8
2025-07-23
Reason
Noble Capital
Price Target
$8
2025-07-23
initiated
Outperform
Reason
Noble Capital initiated coverage of Oncology Institute with an Outperform rating and $8 price target. The medical practice management company specializing in community-based oncology practices manages and operates oncology clinics in five states, notes the analyst, who believes that trends in cost containment "will work in TOI's favor." The firm estimates FY26 revenues of $583.4M, the analyst noted.
B. Riley
Buy
initiated
$6
2025-07-16
Reason
B. Riley
Price Target
$6
2025-07-16
initiated
Buy
Reason
B. Riley initiated coverage of Oncology Institute with a Buy rating and $6 price target. The firm says Oncology Institute is one of the largest oncology specialty value-based healthcare service providers. The company's recent debt facility amendment removed a key financial overhang on the shares, the analyst tells investors in a research note.
BTIG
initiated
$7
2025-05-15
Reason
BTIG
Price Target
$7
2025-05-15
initiated
Reason
BTIG initiated coverage of Oncology Institute with a Buy rating and $7 price target. The company specializes in the treatment and management of cancer patients through a blend of both fee-for-service, capitated, and value-based-care contracts, the analyst tells investors in a research note. The firm says that with the aging of America and rising complex care cost trends amongst some health plans, especially in Medicare Advantage, fee-for-service revenue within Oncology Institute will rise through 2025. Demand for capitated and managed care, sub-contracted risk will likely increase as well, contends BTIG.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Oncology Institute Inc (TOI.O) is -9.23, compared to its 5-year average forward P/E of -6.18. For a more detailed relative valuation and DCF analysis to assess Oncology Institute Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.18
Current PE
-9.23
Overvalued PE
1.73
Undervalued PE
-14.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
204.25
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1623.39
Undervalued EV/EBITDA
-1214.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.49
Current PS
0.00
Overvalued PS
1.17
Undervalued PS
-0.18
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 47487.34% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TOI News & Events

Events Timeline

(ET)
2025-12-01
08:40:00
Oncology Institute Board Member Resigns, Search for New Independent Directors Initiated
select
2025-11-13 (ET)
2025-11-13
16:12:30
Oncology Institute announces Q3 earnings per share of 14 cents, surpassing consensus estimate of 11 cents.
select
2025-09-29 (ET)
2025-09-29
08:08:22
Oncology Institute Forms Alliance with Protocol Behavioral Health
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-25Benzinga
Needham Begins Coverage of Oncology Institute with Buy Rating and Sets Price Target at $5

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

[object Object]
Preview
2.0
11-21Benzinga
Major Stocks Including Elastic, Veeva Systems, and HIVE Digital Decline in Friday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 200 points on Friday.

  • Elastic NV Earnings Report: Elastic NV's shares dropped 12.3% in pre-market trading despite reporting adjusted earnings of 64 cents per share, surpassing analyst expectations, and quarterly revenue of $423.48 million, which also exceeded estimates.

  • Other Stocks Declining: Several other stocks experienced declines in pre-market trading, including Luda Technology Group Ltd (-11.1%), AnaptysBio Inc (-9.7%), and Sigma Lithium Corp (-8.4%).

  • Veeva Systems Performance: Veeva Systems Inc saw a 6.7% drop in pre-market trading despite posting strong third-quarter results and raising its fiscal year earnings and revenue estimates above analyst predictions.

[object Object]
Preview
9.5
11-14NASDAQ.COM
TOI Reports Impressive Q3 2025 Performance, Increases Annual Forecast

  • Strong Q3 Performance: The Oncology Institute Inc. reported Q3 2025 revenue of $136.6 million, a 36.7% increase year-over-year, while narrowing its adjusted EBITDA loss to $3.5 million.

  • Net Loss and Guidance Update: The company experienced a net loss of $16.5 million in Q3 2025 and raised its full-year revenue guidance to $495 million to $505 million, up from $460 million to $480 million.

  • Leadership Changes: Kristin England has been appointed as Chief Administrative Officer to enhance business operations and technology strategy, including AI enablement.

  • Stock Performance: TOI's stock is currently trading at $3.41, reflecting an 11% increase in premarket trading, with a yearly trading range between $0.125 and $4.88.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Oncology Institute Inc (TOI) stock price today?

The current price of TOI is 3.23 USD — it has increased 5.21 % in the last trading day.

arrow icon

What is Oncology Institute Inc (TOI)'s business?

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

arrow icon

What is the price predicton of TOI Stock?

Wall Street analysts forecast TOI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOI is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Oncology Institute Inc (TOI)'s revenue for the last quarter?

Oncology Institute Inc revenue for the last quarter amounts to 136.56M USD, increased 36.70 % YoY.

arrow icon

What is Oncology Institute Inc (TOI)'s earnings per share (EPS) for the last quarter?

Oncology Institute Inc. EPS for the last quarter amounts to -0.14 USD, decreased -22.22 % YoY.

arrow icon

What changes have occurred in the market's expectations for Oncology Institute Inc (TOI)'s fundamentals?

The market is revising Upward the revenue expectations for The Oncology Institute, Inc. (TOI) for FY2025, with the revenue forecasts being adjusted by 5.36% over the past three months. During the same period, the stock price has changed by -2.12%.
arrow icon

How many employees does Oncology Institute Inc (TOI). have?

Oncology Institute Inc (TOI) has 825 emplpoyees as of December 05 2025.

arrow icon

What is Oncology Institute Inc (TOI) market cap?

Today TOI has the market capitalization of 316.79M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free